Thyroxine

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.